Attorney Docket No. 1034082-000005



IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Patent Application of

Istvan Szelenyi et al.

Group Art Unit: 1617

Application No.: 10/089,449

Examiner: SHOBHA KANTAMNENI

Filing Date:

June 28, 2002

Confirmation No.: 9422

Title: NOVEL COMBINATION OF LOTEPREDNOL B2-ADRENOCEPTOR AGONISTS

AMENDMENT/REPLY TRANSMITTAL LETTER

Commissioner for Patents P.O. Box 1450 Alexandria, VA 22313-1450

Sir:			
SII.			

Enc	losed is a reply for the above-identified patent application.					
	A Petition for Extension of Time is also enclosed.					
	Terminal Disclaimer(s) and the \$\infty\$\$ \$\$5.00 (2814) \$\infty\$\$ \$\$130.00 (1814) fee per Disclaimer due under 37 C.F.R. \(\) 1.20(d) are also enclosed.					
	Also enclosed is/are					
_						
	Small entity status is hereby claimed.					
	Applicant(s) requests continued examination under 37 C.F.R. § 1.114 and enclose the \$395.00 (2801) \$790.00 (1801) fee due under 37 C.F.R. § 1.17(e).					
	Applicant(s) requests that any previously unentered after final amendments <u>not</u> be entered. Continued examination is requested based on the enclosed documents identified above.					
	Applicant(s) previously submitted					
	on, for which continued examination is requested.					
	for which continued examination is requested.					
	Applicant(s) requests suspension of action by the Office until at least, which does not exceed three months from the filing of this RCE, in accordance with 37 C.F.R. § 1.103(c). The required fee under 37 C.F.R. § 1.17(i) is enclosed.					
	A Request for Entry and Consideration of Submission under 37 C.F.R. § 1.129(a) (1809/2809) is also enclosed.					

Attorney Docket No. <u>1034082-000005</u>

Application No. __10/089,449

X	No additional claim fee is required.
	An additional claim fee is required, and is calculated as shown below.

		Al	MEN	DE	ED CLAIMS			
	No. of Claims	Highes of Cla Previo Paid	aims ously	•	Extra Claims		Rate	Additional Fee
Total Claims	6	MINUS	20	=	0	x	\$50.00 (1202) =	\$ 0.00
Independent Claims	3	MINUS	3	=	0	×	\$200.00 (1201) =	\$ 0.00
If Amendment adds m	nultiple depend	dent claim	s, add	1 \$	360.00 (1203)			\$ 0.00
Total Claim Amendment Fee					\$ 0.00			
Small Entity Status claimed - subtract 50% of Total Claim Amendment Fee				\$ 0.00				
TOTAL ADDITIONAL CLAIM FEE DUE FOR THIS AMENDMENT				\$ 0.00				

Ш	A check in the amount of	of is enclosed for the fee due
	Charge	to Deposit Account No. 02-4800.
	Charge	to credit card. Form PTO-2038 is attached.

The Director is hereby authorized to charge any appropriate fees under 37 C.F.R. §§ 1.16, 1.17, 1.20(d) and 1.21 that may be required by this paper, and to credit any overpayment, to Deposit Account No. 02-4800. This paper is submitted in duplicate.

Respectfully submitted,

BUCHANAN INGERSOLL PC

P.O. Box 1404 Alexandria, Virginia 22313-1404 (703) 836-6620

Date: April 24, 2006

Loree J. Kim/

Registration No. 53,126



Attorney's Docket No. <u>1034082-000005</u>

THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Patent Application of

Istvan SZELENYI et al.

Application No.: 10/089,449

Filed: June 28, 2002

For: NOVEL COMBINATION OF LOTEPREDNOL β2
MAIL STOP: AF

Group Art Unit: 1617

Examiner: Shobha Kantamneni

Confirmation No.: 9422

<u>AMENDMENT</u>

Commissioner for Patents P.O. Box 1450 Alexandria, VA 22313-1450

ADRENOCEPTOR AGONISTS

Sir:

In complete response to the final Office Action dated January 24, 2006, Applicants submit herewith the following Response.